Premium
Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia ( CLL )
Author(s) -
Hill Brian T.,
Caimi Paolo,
KindwallKeller Tammy,
Habecker Becky,
Kalaycio Matt
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12604
Subject(s) - bendamustine , alemtuzumab , fludarabine , medicine , chronic lymphocytic leukemia , chlorambucil , neutropenia , purine analogue , oncology , rituximab , combination therapy , chemotherapy , gastroenterology , cyclophosphamide , leukemia , transplantation , lymphoma , purine , biochemistry , chemistry , enzyme